ImCheck reveals promising ICT01 results for AML treatment at AACR 2025

In Marseille, France, on March 25, 2025, ImCheck Therapeutics announced that it will present updated results from its clinical study EVICTION at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA. This presentation, scheduled for April 28, 2025, aims to showcase efficacy, safety, pharmacodynamics, and dose selection data regarding ICT01, a novel monoclonal antibody targeting BTN3A to activate T-cells for the treatment of newly diagnosed acute myeloid leukemia (AML). The study highlights promising efficacy results from previous data, which will be elaborated during the poster session. The EVICTION study consists of multiple phases, incorporating both dose-escalation and cohort-expansion for patients with advanced solid or hematologic cancers who have not responded to standard treatments. It consists of combined therapies, including the use of ICT01 with azacitidine and venetoclax for AML patients. The interim results indicate that the combination treatment shows high rates of complete remission, supporting the potential of ICT01 in improving AML treatment outcomes. Moreover, the AACR presentation comes after the data was initially shared at the American Society of Hematology (ASH) Annual Meeting, signaling an ongoing commitment by ImCheck to innovate within cancer treatment through their investigational agents like ICT01. The details regarding the poster presentation are carefully outlined, including session information, time, and authors involved, highlighting the collaborative nature of the research. As the field of oncology advances, ImCheck’s approach utilizing the unique properties of 39,42 T cells promises to bolster the therapeutic landscape, addressing a critical need in treating AML and potentially transforming treatment for other malignancies. This underscores an exciting direction in cancer immunotherapy, which could lead to better patient outcomes and stronger survival rates.